Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Dose-adjusted treatment with venetoclax for 7 days and 5-azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMahmoud GhazalMAMohammed AbbaCGCatharina Gerhards

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 7-day venetoclax treatment reduces complications in AML and MDS patients, indicating comparable efficacy to longer regimens.

Key Points

  • To evaluate the feasibility of a 7-day venetoclax duration combined with standard doses of decitabine in AML and MDS patients.
  • Retrospective analysis of 61 AML and 5 MDS patients
  • Comparison of different durations of venetoclax treatment (7, 14, >14 days)
  • Assessment of overall response rate and complications during treatment
  • Overall response rate across evaluable patients was 74%
  • 7-day venetoclax treatment had fewer complications compared to longer treatment durations
  • No significant differences in overall survival between treatment groups

Cite This Study

Ghazal et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e455https://doi.org/10.1182/blood-2025-1622
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  2. 2Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia2026
  3. 3Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study2025
  4. 4Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia2026
  5. 5Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival2026